Syncom Formulations (India) Ltd. | Small-cap | Healthcare
₹17.37
-1.53%
| Syncom Formulations Stock Comparison:
Syncom Formulations vs Sun PharmaceuticalSyncom Formulations vs Divi's LaboratoriesSyncom Formulations vs Sun Pharma AdvancedSyncom Formulations vs Aarti DrugsSyncom Formulations vs Sequent ScientificSyncom Formulations vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 1.5B
Gross Profit 485.1M 32.58%
Operating Income 164.7M 11.06%
Net Income 176.9M 11.89%

Balance Sheet Metrics

Total Assets 4.1B
Total Liabilities 711.2M
Shareholders Equity 3.4B
Debt to Equity 0.21

Cash Flow Metrics

Revenue & Profitability Trend

Syncom Formulations Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i4.7B2.6B2.2B2.2B2.4B
Cost of Goods Sold i3.1B1.7B1.5B1.5B1.7B
Gross Profit i1.6B942.4M726.4M709.7M722.4M
Gross Margin % i33.9%36.4%32.6%32.6%30.2%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i-294.6M250.3M274.5M177.2M
Other Operating Expenses i513.7M34.2M27.6M23.4M16.6M
Total Operating Expenses i513.7M328.7M277.9M297.9M193.7M
Operating Income i489.4M251.7M164.5M172.7M350.1M
Operating Margin % i10.5%9.7%7.4%7.9%14.6%
Non-Operating Items
Interest Income i-55.2M47.2M39.3M13.5M
Interest Expense i8.6M43.6M31.9M18.3M1.9M
Other Non-Operating Income-----
Pre-tax Income i655.1M339.5M265.7M261.8M407.0M
Income Tax i160.8M86.4M65.0M63.9M115.3M
Effective Tax Rate % i24.5%25.4%24.5%24.4%28.3%
Net Income i494.3M253.1M200.7M197.9M291.7M
Net Margin % i10.6%9.8%9.0%9.1%12.2%
Key Metrics
EBITDA i715.7M423.0M341.2M319.1M448.0M
EPS (Basic) i₹0.57₹0.27₹0.22₹0.26₹0.37
EPS (Diluted) i₹0.57₹0.27₹0.22₹0.24₹0.36
Basic Shares Outstanding i867273684940000000928500000816850000780754000
Diluted Shares Outstanding i867273684940000000928500000816850000780754000

Income Statement Trend

Syncom Formulations Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i7.1M632.9M7.6M2.2M26.4M
Short-term Investments i892.2M681.8M700.2M400.3M713.4M
Accounts Receivable i1.1B1.0B755.1M675.5M748.2M
Inventory i413.3M210.8M212.0M195.1M225.6M
Other Current Assets221.9M377.0K377.0K377.0K377.0K
Total Current Assets i2.7B2.7B1.8B1.4B1.9B
Non-Current Assets
Property, Plant & Equipment i775.3M92.1M60.2M58.3M57.1M
Goodwill i472.0K1.1M1.8M990.0K1.2M
Intangible Assets i-1.1M1.8M990.0K1.2M
Long-term Investments-----
Other Non-Current Assets8.2M2.1M17.6M21.9M7.6M
Total Non-Current Assets i1.4B1.3B2.0B1.7B1.0B
Total Assets i4.1B4.0B3.8B3.1B2.9B
Liabilities
Current Liabilities
Accounts Payable i428.0M241.4M204.5M137.9M293.0M
Short-term Debt i45.8M724.9M831.8M577.9M620.9M
Current Portion of Long-term Debt-----
Other Current Liabilities56.2M5.1M3.5M9.3M7.0M
Total Current Liabilities i593.1M1.1B1.1B782.6M967.0M
Non-Current Liabilities
Long-term Debt i---00
Deferred Tax Liabilities i63.1M49.8M44.2M45.8M44.4M
Other Non-Current Liabilities-3.1K1.2M1.3M1.1M1.8M
Total Non-Current Liabilities i118.1M100.0M86.6M77.6M73.6M
Total Liabilities i711.2M1.2B1.2B860.2M1.0B
Equity
Common Stock i940.0M940.0M940.0M862.5M790.0M
Retained Earnings i-1.0B793.6M621.1M423.2M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i3.4B2.9B2.6B2.2B1.9B
Key Metrics
Total Debt i45.8M724.9M831.8M577.9M620.9M
Working Capital i2.1B1.7B685.3M615.4M931.4M

Balance Sheet Composition

Syncom Formulations Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i655.1M339.8M265.6M261.5M406.7M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-353.4M-330.8M-86.9M174.3M-385.7M
Operating Cash Flow i144.6M-72.6M73.2M338.3M-38.8M
Investing Activities
Capital Expenditures i-99.6M-81.4M-206.3M-113.1M-26.6M
Acquisitions i-----
Investment Purchases i----0
Investment Sales i-----
Investing Cash Flow i56.3M62.3M-64.6M-16.9M31.3M
Financing Activities
Share Repurchases i-----
Dividends Paid i---28.2M--
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i-670.4M-100.8M381.3M96.5M722.3M
Free Cash Flow i134.8M-140.9M-101.1M50.2M-47.2M
Net Change in Cash i-469.6M-111.1M389.9M417.9M714.7M

Cash Flow Trend

Syncom Formulations Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 26.33
Price to Book 5.70
Price to Sales 3.35
PEG Ratio 0.29

Profitability Ratios

Profit Margin 11.64%
Operating Margin 12.38%
Return on Equity 14.45%
Return on Assets 11.96%

Financial Health

Current Ratio 4.55
Debt to Equity 1.34
Beta 1.32

Per Share Data

EPS (TTM) ₹0.67
Book Value per Share ₹3.09
Revenue per Share ₹5.61

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
syncomf16.6B26.335.7014.45%11.64%1.34
Sun Pharmaceutical 3.9T37.925.4515.08%19.29%3.26
Divi's Laboratories 1.6T69.4110.6914.64%23.89%0.03
Sun Pharma Advanced 46.2B-13.29-20.96157.88%-53.22%-1.24
Aarti Drugs 44.7B23.703.2712.28%7.80%44.92
Sequent Scientific 43.5B151.506.182.84%1.85%62.47

Financial data is updated regularly. All figures are in the company's reporting currency.